Sterling Technology | Virtual Data Rooms’ Post

⚕ Genetic Breakthrough: New Technology Holds Promise for Treating Hundreds of Diseases! 🧬 Scientists at the University of Hawaii at Manoa have made a significant leap forward in the fight against genetic diseases! A revolutionary new gene-editing technology, led by Dr. Jesse Owens, has the potential to safely and effectively treat hundreds of hereditary disorders. The technology works by precisely targeting and correcting faulty genes, potentially reversing the effects of genetic diseases. This could lead to life-changing treatments for millions of people worldwide. Could gene editing be the key to unlocking a new era of human health? ➡ Follow me for more news and insights on disruptive tech, science, innovation and the future 👨💻 #Genetics #GeneEditing #GeneticTherapy #BioTech #MedTech https://lnkd.in/e4Qqjqhx

New #AI method, #LINGER, cracks the code on gene regulation! 💡 LINGER, developed by Clemson University scientists, infers gene regulatory networks from single-cell multiomics data by integrating atlas-scale bulk data and prior knowledge. It outperforms existing methods and enables interpreting disease variants from expression data alone. Quick Read: https://lnkd.in/gYViayW2 #bioinformatics #genomics #machinelearning #generegulation #bigdata #sciencenews

AI used to create the first open source gene editor. A promising tool to foster the research in this field and accelerate #crisprtherapy development. #crispr #crisprcas9 #genetherapy #celltherapy #geneediting #genomeediting #rnatherapeutics #genometherapy https://lnkd.in/e2FkVChk

AI-Driven Gene Editing Promises Faster Disease Control - Generative A.I. in Gene Editing: Profluent has developed OpenCRISPR-1, a gene editor using AI technology similar to ChatGPT, aimed at devising blueprints for biological mechanisms capable of DNA editing. - Precision and Speed in Disease Control: This new AI-generated gene editing technology offers potential for battling illnesses with unprecedented precision and speed, enhancing future healthcare applications. - CRISPR-Based Technology Advancements: Leveraging CRISPR, a Nobel Prize-winning method, Profluent’s AI creates new gene editors by analyzing extensive biological data, indicating significant advancements in gene therapy. Subscribe to our daily newsletter here for more AI news https://lnkd.in/dA4Gq8UY #Healthcare #Innovation #ArtificialIntelligence #Research #Biotechnology #Futurism #Science #Health #Sustainability #Technology #AI

CRISPR in Gene Editing and Rare Disease - Growing Trends in Multiomic Analysis 🔬 Advanced Gene Editing: CRISPR technology is changing the way we can perform genetic modifications, targeting genes responsible across disease. #GeneEditing #CRISPR 💡 Potential Benefits: The application of CRISPR in lcan lead to disease resistance and mitigating age-related diseases. For example, a massive 98% reduction in swelling attacks in hereditary angioedema, hence its entry into Phase 3 clinical trials. See more at: https://lnkd.in/evkqTURF #Biotech #AgingResearch 🔬 Bioinformatics Analysis at IDL: Validating and analysing gene editing efficiency, monitoring patient-specific genetic responses, and integrating multi-omics data to validate long-term efficacy and safety outcomes are crucial and are expertise at Independent Data Lab. Our collaboration ensures data-driven decision-making in clinical trials. #Bioinformatics #GeneEditing #ClinicalTrials Image credits: https://lnkd.in/eSz6Ek8X

New #AI method, #LINGER, cracks the code on gene regulation! 💡 LINGER, developed by Clemson University scientists, infers gene regulatory networks from single-cell multiomics data by integrating atlas-scale bulk data and prior knowledge. It outperforms existing methods and enables interpreting disease variants from expression data alone. Quick Read: https://lnkd.in/gYViayW2 #bioinformatics #genomics #machinelearning #generegulation #bigdata #sciencenews #biotechnology

🔍 Is WES (Whole Exome Sequencing) truly capturing the "whole" exome? Let's discuss. Emerging evidence suggests that WES technologies may exhibit preference—primarily targeting coding exonic regions, while non-coding exonic regions are often overlooked. This has significant implications for our understanding of gene regulation, genetic variation, and the functional importance of non-coding exons. ⚠️ To improve clarity and avoid misinterpretation, we propose a clearer terminology shift: Coding Exome Sequencing (CES) could replace WES when technologies are specifically assessing coding exonic regions. ✅ Why is this important? 1️⃣ Accurate communication: Clearly naming the technology helps researchers and clinicians understand what is being assessed. 2️⃣ Comprehensive insight: The non-coding exome plays a critical role in gene expression regulation and disease mechanisms. Ignoring this limits our understanding of the genome’s full functional landscape. 3️⃣ Improved annotation: A thorough measurement and annotation of non-coding exonic regions across species will enhance transcript maps, improving the interpretation of genetic variations. As the non-coding genome continues to gain attention, now is the time to refine our terminology and expand our focus. Accurate and transparent language will lead to better data interpretation and unlock new biological insights. 🌱 What are your thoughts on this shift in terminology and focus? Let’s work together to evolve our understanding of the “whole exome”! #Genomics #WES #NonCodingExome #CodingExomeSequencing #CES #NGS #GenomeResearch

Dear Gene Therapy Experts, Kindly visit https://lnkd.in/gKu-bQ3F for more information and to register your participation. We look forward to welcoming you to Paris for what promises to be a rewarding and enriching experience. We are delighted to extend this invitation to you and all gene therapy experts to participate in the 2nd International Gene Therapy Conference and Exhibition, scheduled for December 4-6, 2024 in Paris. This event promises to be an exceptional gathering of leaders, researchers, and innovators in the field of gene therapy. It will feature insightful discussions, presentations of cutting-edge research, and opportunities for networking with peers and industry professionals. Event Details: Date: December 4-6, 2024 Location: Paris, France Join us as we explore the latest advancements and breakthroughs in gene therapy, exchange ideas, and foster collaborations that will shape the future of this transformative field. Stay tuned Gene Forum for more updates! #GeneForum2024 #Genomics #Genetics #GeneEditing #CRISPR #Biotechnology #GeneticEngineering #GeneTherapy #PrecisionMedicine #Bioinformatics #GeneticResearch #Genome #GeneSequencing #HealthcareInnovation #MedicalResearch #MolecularBiology #GeneticCounseling #GeneExpression #GeneticDiagnostics #Biomarkers #EthicalGenetics #FutureOfMedicine #GeneticScience #GeneticData #GenomeEditing #GeneRegulation #GenomicMedicine #BiomedicalScience #GeneticVariation #GeneDiscovery #GeneticTechnologies #GenomicData #HumanGenetics #GeneticMedicine #GenomicAnalysis #GeneSequencer #GeneticHealth #GeneTherapeutics #GenomeSequencing #GenomicsResearch #GeneticInformation #PrecisionGenomics #GeneMapping #GenomeEngineering #GenomicTechnologies #GeneForum2024Conference

IS THIS SUCCESS❓ This recent gene editing study has made the global news, and many friends sent it my way because it relates to Vicky’s condition (but a different gene). The scientific progress is absolutely incredible. The teams at Mass Eye and Ear, Oregon and Philadelphia did an amazing job, many of whom I personally know, and I admire. I’m happy for the patients who took part in this trial and saw improvements in their vision. When started, it was the very first gene editing done directly on the human body —ophthalmology leading the way again! But here’s the thing: this is only partly a success story. The study completed almost two years ago and just got published. What’s often missed in the headlines is that the work is currently paused. Yes, some people saw big improvements, and CRISPR is promising. But this wasn't enough to demonstrate a commercial return, leading to a lack of investment in further clinical development to ultimately make it available to patients. There remains no treatment for conditions like this (nor for Vicky's one), and this work is simply not progressing (yet). I absolutely get the P&L challenges and investor expectations. But this is another example of how traditional commercial models are lagging behind scientific advancements. We often shy away from small patient populations and rare diseases, failing to see that addressing these can pave the way for a (near) future of personalized medicine. We need to rethink how we bring these scientific advancements to patients. We need, among others: 🏥Better policies that encourage investments in rare disease and not hamper them 🚩Better regulatory frameworks to address the challenges of small patient population trials 👫Better partnership between industry and patients 🧫More efficient manufacturing to reduce the cost What else? Personalized medicine is here. We just need to find a way to access it… Link to the study https://lnkd.in/eQMqStTk #MyOwnViews #PersonalizedMedicine

What if we could edit DNA like fixing a typo in a Word document? 📑 Just imagine a future where genetic disorders are cured with a simple edit. Thanks to Tome Biosciences, that future is closer than ever. Founded by MIT scientists Omar Abudayyeh and Jonathan Gootenberg, Tome is breaking new ground in gene therapy. Their cutting-edge tech doesn’t just treat genetic diseases—it fixes them at the source by inserting healthy genes precisely where they’re needed. I had an inspiring conversation with Tome’s Chief Scientific Officer, Jonathan (John) Finn, where we dove into: - How Tome is transforming gene therapy with programmable genomic integration (PGI) - The science behind their breakthrough PACE and IPGI technologies - Why Tome’s approach is a game-changer, going beyond traditional gene editing to actually repair genes Curious to learn more? Our latest podcast episode is now live! Check out the link in the comments to listen or watch.